Chromosome 17q21.31 microdeletion was one of the first genomic disorders identified by chromosome microarrays. We report here the clinical and molecular characterization of a new series of 14 French patients with this microdeletion syndrome. The most frequent clinical features were hypotonia, developmental delay and facial dysmorphism, but scaphocephaly, prenatal ischemic infarction and perception deafness were also described. Genotyping of the parents showed that the parent from which the abnormality was inherited carried the H2 inversion polymorphism, confirming that the H2 allele is necessary, but not sufficient to generate the 17q21.31 microdeletion. Previously reported molecular analyses of patients with 17q21.31 microdeletion syndrome defined a 493 kb genomic fragment that was deleted in most patients after taking into account frequent copy number variations in normal controls, but the deleted interval was significantly smaller (205 kb) in one of our patients, encompassing only the MAPT, STH and KIAA1267 genes. As this patient presents the classical phenotype of 17q21.31 syndrome, these data make it possible to define a new minimal critical region of 160.8 kb, strengthening the evidence for involvement of the MAPT gene in this syndrome.
Introduction
Array comparative genomic hybridization (aCGH) has revolutionized the diagnosis of mental retardation through the use of a "reverse phenotyping" approach making it possible to identify recurrent genomic rearrangements before their clinical description [1] . Such techniques led to the recent characterization of novel microdeletion and microduplication syndromes [2, 3, 4] . A recurrent 17q21.31 microdeletion [Mendelian Inheritance in Man (MIM) #610443], resulting in the loss of a 500 to 650 kb region between low-copy repeat (LCR) regions, was first described in 2006 in mentally retarded individuals with a clearly recognizable clinical phenotype of mental retardation, hypotonia and characteristic facial features [5, 6, 7] . The complex genomic architecture of this microdeletion, with large clusters of LCRs at the breakpoints, suggested an underlying mechanism of non allelic homologous recombination (NAHR) [8] . A common 900 kb inversion polymorphism occurs in this region, and chromosomes with the inverted fragment in different orientations correspond to two different haplotypes, H1 and H2 [9] . The direct orientation of LCRs flanking the deleted fragment in the H2 haplotype predisposes the offspring to NAHR, favoring the generation of this microdeletion [9] . This mechanism is similar to that described for predisposing inversion polymorphisms in other microdeletion syndromes, such as Williams-Beuren syndrome (WBS), Angelman syndrome, Sotos syndrome [10] , and 15q13.3 microdeletion syndrome [11] . For several chromosomal loci subject to NAHR, reciprocal deletion and duplication syndromes have been identified, including WBS and 7q11.23 duplication [12] , SmithMagenis syndrome and Potocki-Lupski syndrome [13] , Prader-Willi syndrome/Angelman syndrome and 15q11q13 duplication [14] , Velocardiofacial syndrome and 22q11.2 duplication [15] . However, deletions are generated at a higher rate than their reciprocal duplications [16] . The first case of duplication of the 17q21.31 region was not described until 2007 [17] , in a patient with severe psychomotor developmental delay, facial dysmorphism, inserm-00541962, version 1 -1 Dec 2010 macrocephaly, abnormally broad fingers and toes and hirsutism. Four other patients with 17q21.31 microduplication and behavior problems and poor social interaction have also recently been reported [18] .
With the use of higher resolution arrays, taking frequent copy number variations in normal controls into account, the minimal critical region involved in this 17q21.31 microdeletion syndrome was recently refined to a 424 kb region encompassing at least six genes: C17orf69, the corticotropin-releasing hormone receptor 1 gene (CRHR1) (MIM #122561), the intramembrane protease 5 gene (IMP5) (MIM #608284), the microtubule-associated protein tau gene (MAPT) (MIM #157140), the saitohin gene (STH) (MIM #607067), and KIAA1267 [19] . MAPT seems to be the most interesting of these genes for further study, because it is strongly expressed in the brain and has been implicated in several neurodegenerative diseases [20] .
The largest series of patients with 17q21.31 microdeletion syndromes reported to date was studied by Koolen et al. [19] , who identified a clinically recognizable phenotype, including developmental delay, childhood hypotonia and facial dysmorphism. This phenotype was recently expanded to include aortic root dilatation, recurrent joint dislocation, conductive hearing loss, dental abnormalities, the persistence of fetal fingertip pads [21] , iris-choroid coloboma and partial situs inversus [22] .
We present here a new series of 14 patients with the 17q21.31 microdeletion syndrome ascertained through the network of French array CGH platforms (http://www.renapa.univmontp1.fr/) and the BACH database (https://www.genopole-lille.fr/bach/menu.php), confirming the described phenotype, refining the minimal critical region and providing further inserm-00541962, version 1 -1 Dec 2010 support for the role of MAPT in this syndrome. We also discuss the results of H1/H2 genotyping and parent-of-origin analysis, comparing our results with published findings.
Materials and methods

Patients
A collaborative study involving the French array CGH platforms analyzing patients with mental retardation (MR), dysmorphic features and multiple congenital abnormalities (MCA) was set up for the molecular and clinical characterization of all unpublished French patients carrying the 17q21.31 microdeletion. Molecular cytogenetics analyses of 2672 MR/MCA patients showed that 14 of these patients had a 17q21.31 microdeletion. Informed consent for genetic testing was obtained from all tested patients and their relatives.
Molecular cytogenetics
Two platforms were used for genomic copy number analyses, which were carried out according to the manufacturer's protocol (Agilent Technologies, Santa Clara, CA, USA): the Human Genome CGH Microarray 44K (for all patients except patient 7) and 244K (patient 7). When material from the parents was available, a family study was performed (12 patients).
H1/H2 genotyping was carried out for individuals with the 17q21.31 deletion and their parents, by PCR amplification of a region encompassing a potential 238 bp deletion in the intron 9 of the MAPT gene associated with the H2 background [9, 19] .
The parental origin of the chromosome with the deletion was determined with the DG17S142 dinucleotide marker and three to five additional variable number tandem repeats within the deleted region, together with two flanking short tandem repeats, D17S810 and D17S920 [19] .
Marker analyses were carried out according to standard procedures and data were interpreted with GeneMapper (v. 4.0) software (Applied Biosystems, Foster City, CA, USA).
Results
Array CGH results
All the patients studied had an overlapping heterozygous deletion of the 17q21.31 interval (Fig. 1 ). Oligonucleotide array CGH data identified a 493 kb region (chr17:41,073,486-41,566,599) (hg18-build36) as deleted in 11 affected individuals. In one patient (patient 7), the deletion was larger, being somewhere between 675 kb and 810 kb in size and extending to the distal part of the chromosome. However, the distal breakpoint region was a site of frequent copy number variation (CNV) in normal controls. The proximal breakpoint was also found to be located in a variable region. This may account for the subtle shifts in the breakpoints observed, as in patient 10 (chr17:41,212,860-41,566 ,599) (hg18-build36). By contrast, patient 3 had a significantly smaller deletion, of only 205 kb (chr17:41,310,123-41,515,622) (hg18-build36).
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FISH studies confirmed the 17q21.31 deletion in patients 1, 2 and 4 to 13, with RP11-597L17 and/or RP11-656O14, RP11-413P22, RP11-669E4 or RP11-769P22 found to be deleted. The deletion identified in patient 3 was validated by MLPA, which confirmed the presence of a heterozygous deletion for the two probes targeting MAPT exons 8 and 11, whereas the signal obtained for the CRHR1 probe (exon 8) showed that this gene was not deleted (data not shown).
Clinical description (Table 1) The most typical clinical features of 17q21.31 syndrome include hypotonia, developmental delay, overly friendly/amiable behavior and facial dysmorphism with a long face, a tubular or pear-shaped nose and a bulbous nasal tip (Fig. 2) . The principal clinical characteristics of patients 1 to 14 are described in Table 1 . Additional features are described below.
Patient 1 is the first and only child of unrelated parents. The pregnancy was complicated by intrauterine growth retardation (IUGR), which was interpreted as originating from a vascular cause. This child, a boy, was born at 39 weeks by cesarean section. Early problems included an inability to suck effectively and feeding problems, with enterocolitis causing ulcer and necrosis. Molecular analysis of the GJB2 and GJB6 genes were performed because of deafness, but no alteration was detected.
Patient 2 is the second child of Moroccan and Breton parents. Prenatal imaging
showed right hydronephrosis. A ventricular septal defect (VSD) observed at birth regressed spontaneously. This patient presented bronchiolitis and pyelonephritis at the age of six months, feeding problems, fainting due to hypotonia at the age of nine months, and epileptic seizures at the age of three years. He has a short stature and low weight (-2SD) and is prone to Patient 6 presented initial hypotonia, followed by seizures at the age of 14 months.
His testes were located in the inguinal canal.
Patient 7 was delivered at 31 weeks of gestation, by cesarean section due to acute fetal distress. Scaphocephaly was recorded, leading to the detection of metopic craniostenosis at the age of two years.
inserm-00541962, version 1 -1 Dec 2010
Patient 8 presented feeding difficulties in the neonatal period. Severe speech dyspraxia became apparent in infancy.
Patient 9 is the second child of non consanguineous parents. She was hypotonic as a baby, with tongue protrusion. She also presented feeding difficulties and constipation.
Patient 10 is the third child of unrelated parents. The pregnancy was uncomplicated.
A bilateral cleft lip was discovered at birth, with no damage to the alveolar ridge or palate.
This patient is very sociable and cheerful. Her skin is very dry.
Patient 11 presented delayed development of axial tonus at four months. Seizures first appeared at the age of eight months, with temporo-occipital foci.
Patient 12 presented hypotonia and feeding difficulties during the neonatal period. He also displayed cryptorchidism requiring surgical treatment.
Patient 13 presented developmental delay, more serious for psychomotor development than for language.
For patient 14, the neonatal period was marked by feeding difficulties and hypotonia.
Genotyping
The genotyping of 24 parents (in 12 families) showed that the deletion was inherited from the mother in seven families and from the father in four families. In the remaining family, the panel of repeat markers across the deleted region could not distinguish between the parental chromosomes ( Table 2) .
Fifteen of the 24 parents tested were heterozygous for the H2 inversion, whereas four were homozygous for this inversion. The parent from which the inversion originated carried the H2 inversion polymorphism in at least a heterozygous state.
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Discussion
All the patients with 17q21.31 microdeletion syndrome reported here were identified by array CGH screening, by the network of French array CGH platforms, of large heterogeneous cohorts of patients with mental retardation. The calculated prevalence of 17q21.31 syndrome in our French cohort was 0.52% (14 of the 2672 patients tested), which is of the same order of magnitude as previous estimates (0.64% for Koolen et al. [19] , 0.5% for Sharkey et al. [22] ).
Given the copy number polymorphisms located at either end of the deleted region, we investigated the size of the deletion in 11 of our patients conforming to the DECIPHER description of 17q21.31 syndrome as a standard deletion extending from 40.99 to 41.57 Mb.
However, the critical region of 17q21.31 was recently refined and narrowed to a 424 kb genomic interval (chr17:41,046,729-41,470,954, hg18) by analyses based on SNP arrays and ultra-high density custom oligonucleotide arrays targeting the 17q21.31 region and excluding frequent copy number variations in normal controls [19] . In our patient 3 with classical clinical characteristics, including facial features (Fig. 2) , a smaller, partially overlapping deletion was observed (chr17: 41,310,123-41,515,622, hg18-build36) . This deletion encompasses only MAPT, STH and KIAA1267, leaving the patient with two copies of the CRHR1 gene, but the phenotype of this patient was no milder than that of the other patients.
Comparison of this 205 kb deletion with the 424 kb critical region described by Koolen et al. degeneration [25] , or Alzheimer's disease [26] , in which abnormal deposition of insoluble tau protein is observed, with a decrease in the concentration of the normal soluble tau molecule in patients' brains, affecting the assembly, dynamic behavior and spatial organization of microtubules in neurons and glial cells [27] . The microdeletion event observed in 17q21.31 syndrome results in MAPT haploinsufficiency. In mice, Mapt haploinsufficiency in tau -/-animals affects microtubule density and stability in small-caliber axons [28] , resulting in a murine phenotype including muscle weakness in a wire-hanging test, hyperactivity in a novel environment and impairment in contextual fear conditioning [29] . However, screening for mutations in MAPT in 122 individuals with a phenotype suggestive of 17q21.31 syndrome identified no disease-associated variants [19] .
The facial features described by other groups [19, 21] was found in our patients, but become increasingly obvious with age. Consistent with one patient described by Tan et al. [21] , two of our patients presented scaphocephaly revealing metopic craniostenosis. All our patients were hypotonic, with global developmental delay predominant over language problems. Other defects (ophthalmologic, cardiac, urologic, central nervous system, joint hypermobility, hip dysplasia) were commonly noted. Prenatal ischemic infarction was diagnosed in patient 3, as also reported for one of the patients described by Koolen et al. [19] . Tan et al. [21] reported hearing defects resulting from chronic otitis. One of our patients (patient 1) was deaf, but this problem was due to a neurosensorial defect rather than conductive problems, despite the occurrence of numerous ENT infections in early infancy.
The 17q21.31 genomic region contains a 900 kb inversion polymorphism generating two highly divergent haplotypes, H1 and H2, that are transmitted en bloc [9] . The frequency of the H2 lineage has been reported to be about 20% in the European population, whereas this inserm-00541962, version 1 -1 Dec 2010
haplotype is rare in Africans and almost never detected in East Asians. We indirectly identified this H2 inversion in 23 of the 48 chromosomes from parents tested and, for each trio, the parent from which the chromosome 17 deletion was inherited carried the H2 inversion polymorphism in either the homozygous or heterozygous state, giving a significantly higher frequency. Seven of the deletions were of maternal origin and four were of paternal origin. Combining these data with those obtained by Koolen et al. [19] , we can assume that there is no significant bias in the parental origin of the chromosome bearing the deletion. Unfortunately, we were unable to obtain DNA from the parents of patient 3. The H2
haplotype confers a genomic architecture in which LCR subunits are directly oriented, mediating the NAHR event leading to deletion [30] . However, as the frequency of 17q21.31 deletion in the offspring of H2 inversion carriers is low, the H2 allele is necessary, but not sufficient to generate the 17q21.31 deletion [19] .
Considering our French series of 14 patients with the 17q21.31 microdeletion syndrome and previous reports of 22 [19] and 11 patients [21] , it is clear that this microdeletion syndrome is clinically significant. Our study also narrowed the definition of the minimal deleted region to a restricted interval of 160.8 kb, strengthening the implication of the MAPT gene in this syndrome.
Acknowledgments
We thank all the staff of the Biogenouest  -IBiSA (Rennes) transcriptomics platform. We also thank our colleagues for referring patients, and the patients and their families for participating in this study. Patients 1, 2, 4, 5, 6, 8, 9, 11, 12, 13, 14 (493 kb) A blank square means that the characteristic was not assessed, a "minus" signs (-) indicates that it was absent.
